Hi Guys, I spent around 15 years in medical research and spent...

Hi Guys, I spent around 15 years in medical research and spent time in biomarker development. The reported results are EXCELLENT. EARLY DETECTION is an important part for early treatment. The number of Subjects used also acceptable in both studies. DO NOT underestimate these results.

... following is the Ovarian cancer results (47 Ovarian Cancer Patients & 22 Cancer-Free Control subjects)

Dr Shewell
reported that serum from 47 patients with all stages of ovarian cancer had significantly elevated mean
levels of Neu5Gc glycans compared to 22 cancer-free control individuals. She concluded that detection of
Neu5Gc-glycans using SubB2M has the potential to be used as a diagnostic marker for the detection of
early-stage ovarian cancer, as well as a tool for monitoring disease progression in late-stage cancer.

Breast Cancer Results(96 Breast Cancer Patients & 22 Cancer-Free Control subjects):

Dr Shewell reported that serum from 96 patients with all stages of breast cancer had significantly elevated
mean levels of Neu5Gc glycans compared to 22 cancer-free control individuals when assayed by surface
plasmon resonance. The research also demonstrated the potential of SubB2M for the monitoring of
patients for disease recurrence. Dr Shewell concluded that detection of Neu5Gc-glycans using SubB2M
has the potential to be useful as a diagnostic marker for the detection of early-stage breast cancer, as well
as a tool for monitoring disease progression in late-stage cancer.

BOTH results will bring huge business opportunities.

Not only early diagnosis and during the treatment the assay can use to monitor the progress of the patients.
"We will continue to collaborate with Griffith University to develop and validate commercial assays
for monitoring treatment response"

Based on my experience and knowledge I evaluated the work.